MOATAZEDI DAVID 4
4 · Evolus, Inc. · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Evolus (EOLS) CEO David Moatazedi Sells 116,720 Shares
What Happened
- David Moatazedi, President & Chief Executive Officer of Evolus, had 67,489 performance shares vest and settle on March 16, 2026 (issued at $0 exercise price). He sold 116,720 shares in an open-market transaction on March 17, 2026 for a weighted average price of $4.89, generating approximately $570,562. The share issuance on March 16 resulted from the Certification of PSUs earned at 100% of target.
Key Details
- Transaction dates: March 16, 2026 (PSU settlement/exercise); March 17, 2026 (open-market sale). Form filed March 18, 2026 (timely).
- Sale price(s): weighted average $4.89; trade prices ranged $4.8874–$5.015 (multiple trades).
- Shares involved: 67,489 shares issued/received on settlement; 116,720 shares sold in the market.
- Proceeds: roughly $570,562 from the open-market sales.
- Shares owned after transaction: not specified in the provided excerpt; 67,488 of the originally granted 134,977 PSUs remain outstanding and are scheduled to vest Feb 7, 2027 (per footnote).
- Notable footnotes: (F1) 134,977 PSUs granted in Feb 2024, 50% vested/settled Mar 16, 2026; (F2) sales effected pursuant to a Rule 10b5‑1 plan to cover tax withholding from PSU/RSU vesting; (F3) seller offers to provide detailed trade-by-trade info on request.
Context
- This was not a market-timing purchase signal: shares were issued upon PSU vesting and many were sold under a pre-established 10b5‑1 plan to cover tax obligations. The filing appears timely (filed within the standard Form 4 window). For derivative/award activity: PSUs were certified and settled into common shares; the insider sold shares rather than a purchase indicating routine tax/liquidity management, not necessarily a view on company prospects.
Insider Transaction Report
Form 4
Evolus, Inc.EOLS
MOATAZEDI DAVID
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-16+67,489→ 735,089 total - Sale
Common Stock
[F2][F3]2026-03-17$4.89/sh−116,720$570,562→ 618,369 total - Exercise/Conversion
Performance Restricted Stock Units
[F1]2026-03-16−67,489→ 67,488 total→ Common Stock (67,489 underlying)
Footnotes (3)
- [F1]As previously reported, on February 7, 2024, the Reporting Person was granted 134,977 performance restricted stock units ("PSUs") at target pursuant to the Evolus, Inc. 2017 Omnibus Incentive Plan. The PSUs were subject to performance conditions based on certain pre-specified revenue and defined non-GAAP operating profit measured over the Issuer's 2024 and 2025 fiscal years. The Compensation Committee certified achievement at 100% of target, resulting in 134,977 earned PSUs. Of the earned PSUs, 50% vested and settled on March 16, 2026, resulting in the issuance of 67,489 shares of the Issuer's common stock. The remaining 67,488 PSUs remain outstanding and are scheduled to vest on February 7, 2027, subject to continued service. The number of shares reported reflects rounding adjustments applied in accordance with the terms of the award and administrative procedures.
- [F2]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of multiple PSU and restricted stock unit awards.
- [F3]The shares were sold in multiple trades at prices ranging from $4.8874 to $5.015. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Signature
/s/ Jeffrey J. Plumer, as attorney-in-fact for David Moatazedi|2026-03-18